428 related articles for article (PubMed ID: 20729332)
1. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes.
Kamphorst AO; Guermonprez P; Dudziak D; Nussenzweig MC
J Immunol; 2010 Sep; 185(6):3426-35. PubMed ID: 20729332
[TBL] [Abstract][Full Text] [Related]
2. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
3. Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination.
Reuter A; Panozza SE; Macri C; Dumont C; Li J; Liu H; Segura E; Vega-Ramos J; Gupta N; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
J Immunol; 2015 Mar; 194(6):2696-705. PubMed ID: 25653426
[TBL] [Abstract][Full Text] [Related]
4. Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells.
Tagliani E; Guermonprez P; Sepúlveda J; López-Bravo M; Ardavín C; Amigorena S; Benvenuti F; Burrone OR
J Immunol; 2008 Mar; 180(5):3201-9. PubMed ID: 18292544
[TBL] [Abstract][Full Text] [Related]
5. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
6. Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.
Ho NI; Camps MGM; de Haas EFE; Ossendorp F
Eur J Immunol; 2018 Jul; 48(7):1164-1173. PubMed ID: 29676785
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.
Rosalia RA; Quakkelaar ED; Redeker A; Khan S; Camps M; Drijfhout JW; Silva AL; Jiskoot W; van Hall T; van Veelen PA; Janssen G; Franken K; Cruz LJ; Tromp A; Oostendorp J; van der Burg SH; Ossendorp F; Melief CJ
Eur J Immunol; 2013 Oct; 43(10):2554-65. PubMed ID: 23836147
[TBL] [Abstract][Full Text] [Related]
8. CD13 regulates dendritic cell cross-presentation and T cell responses by inhibiting receptor-mediated antigen uptake.
Ghosh M; McAuliffe B; Subramani J; Basu S; Shapiro LH
J Immunol; 2012 Jun; 188(11):5489-99. PubMed ID: 22544935
[TBL] [Abstract][Full Text] [Related]
9. Stroma-dependent development of two dendritic-like cell types with distinct antigen presenting capability.
Periasamy P; O'Neill HC
Exp Hematol; 2013 Mar; 41(3):281-92. PubMed ID: 23178375
[TBL] [Abstract][Full Text] [Related]
10. Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.
Farrand KJ; Dickgreber N; Stoitzner P; Ronchese F; Petersen TR; Hermans IF
J Immunol; 2009 Dec; 183(12):7732-42. PubMed ID: 19923446
[TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
[TBL] [Abstract][Full Text] [Related]
12. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
[TBL] [Abstract][Full Text] [Related]
13. FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells.
Boross P; van Montfoort N; Stapels DA; van der Poel CE; Bertens C; Meeldijk J; Jansen JH; Verbeek JS; Ossendorp F; Wubbolts R; Leusen JH
J Immunol; 2014 Dec; 193(11):5506-14. PubMed ID: 25355925
[TBL] [Abstract][Full Text] [Related]
14. MHC class I/peptide transfer between dendritic cells overcomes poor cross-presentation by monocyte-derived APCs that engulf dying cells.
Qu C; Nguyen VA; Merad M; Randolph GJ
J Immunol; 2009 Mar; 182(6):3650-9. PubMed ID: 19265143
[TBL] [Abstract][Full Text] [Related]
15. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture.
Schnorrer P; Behrens GM; Wilson NS; Pooley JL; Smith CM; El-Sukkari D; Davey G; Kupresanin F; Li M; Maraskovsky E; Belz GT; Carbone FR; Shortman K; Heath WR; Villadangos JA
Proc Natl Acad Sci U S A; 2006 Jul; 103(28):10729-34. PubMed ID: 16807294
[TBL] [Abstract][Full Text] [Related]
16. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.
Pooley JL; Heath WR; Shortman K
J Immunol; 2001 May; 166(9):5327-30. PubMed ID: 11313367
[TBL] [Abstract][Full Text] [Related]
17. Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles.
Keller SA; Bauer M; Manolova V; Muntwiler S; Saudan P; Bachmann MF
J Immunol; 2010 Jan; 184(1):26-9. PubMed ID: 19949081
[TBL] [Abstract][Full Text] [Related]
18. Thymic but not splenic CD8⁺ DCs can efficiently cross-prime T cells in the absence of licensing factors.
Dresch C; Ackermann M; Vogt B; de Andrade Pereira B; Shortman K; Fraefel C
Eur J Immunol; 2011 Sep; 41(9):2544-55. PubMed ID: 21748731
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of MHC:peptide complexes by dendritic cells contributes to the generation of antiviral CD8+ T cell immunity in vivo.
Smyth LA; Hervouet C; Hayday T; Becker PD; Ellis R; Lechler RI; Lombardi G; Klavinskis LS
J Immunol; 2012 Sep; 189(5):2274-82. PubMed ID: 22821960
[TBL] [Abstract][Full Text] [Related]
20. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
